LUX-Lung 3

一行要約

未治療 EGFR 変異陽性 NSCLC 1L における 2nd-gen Afatinib vs Cisplatin/Pemetrexed の phase III。PFS HR 0.58 (11.1 vs 6.9 mo) で有意に PFS を延長し、第 2 世代 irreversible EGFR-TKI の 1L 有効性を確立。Common mutation (ex19del / L858R) では HR 0.47 とさらに顕著な PFS 延長を示した。

試験デザイン

• 対象: Stage IIIB/IV NSCLC、EGFR 変異陽性 (common + uncommon mutations 含む)、未治療、ECOG PS 0-1、N=345 (2:1)
• 介入群 (n=230) : Afatinib 40 mg/day (PD or intolerable toxicity まで)
• 対照群 (n=115) : Cisplatin 75 mg/m2 + Pemetrexed 500 mg/m2 Q3W、最大 6 cycles
• 層別化: 変異タイプ (ex19del / L858R / other)、人種 (Asian / non-Asian)
• 主要評価項目: PFS (独立中央判定)

主要結果

• PFS (primary、全登録) : HR 0.58 (95% CI 0.43–0.78, p=0.001)、median 11.1 vs 6.9 mo
• PFS (common mutations) : HR 0.47 (95% CI 0.34–0.65)、median 13.6 vs 6.9 mo — ex19del と L858R の双方で benefit
• ORR: 56% vs 23%
• OS: 全体 28.2 vs 28.2 mo (HR 0.88, p=0.39) — crossover と後治療の影響で有意差なし。ex19del subgroup では OS HR 0.78 (31.4 vs 18.4 mo)
• Grade ≥3 AE: Afatinib で下痢 14%、皮疹 16%、口内炎 8%。用量調整 (40→30→20 mg) で manageable
• Uncommon mutations: G719X / L861Q / S768I では PFS benefit あり、exon 20 insertion では benefit なし

臨床的意義

• 2nd-gen EGFR-TKI の 1L 確立: Gefitinib / Erlotinib に続く irreversible pan-ErbB blocker として承認根拠。IPASS、NEJ002、WJTOG3405 が確立した 1st-gen TKI 1L に対し、「世代進化」の概念を初めて clinical data で提示
• Uncommon mutation への活性: G719X / L861Q / S768I への有効性は Afatinib の差別化ポイントとなり、uncommon mutation NSCLC の治療選択に影響
• LUX-Lung シリーズ: LUX-Lung-7 (Afatinib vs Gefitinib head-to-head) への展開
• 2nd vs 3rd-gen の位置づけ: FLAURA で Osimertinib が 1L standard を獲得した後、Afatinib 1L は限定的使用 (uncommon mutations、sequential 戦略)

Open Questions

• Uncommon EGFR mutation での Afatinib vs Osimertinib: Head-to-head data の欠如
• Afatinib → Osimertinib sequential の OS: LUX-Lung 7 / GioTag study で示唆された sequential benefit の long-term validation
• Exon 20 insertion への新規薬剤: Amivantamab / Mobocertinib が参入した後の Afatinib の位置づけ

重要論文 Top 10

1. ★★★★★ Sequist et al. JClinOncol 2013 — Primary publication — PFS HR 0.58、2nd-gen TKI 承認根拠
2. Yang et al. (LUX-Lung 6) — Asian 対象 companion trial — Afatinib vs Gemcitabine/Cisplatin
3. Yang et al. (OS pooled) — LUX-Lung 3+6 pooled OS — ex19del で OS benefit
4. ★★★★ Park et al. LancetOncol 2016 (LUX-Lung-7) — Afatinib vs Gefitinib head-to-head
5. Soria et al. (FLAURA) — 3rd-gen Osimertinib 1L — 2nd-gen を超える efficacy

関連エンティティ・概念

• 薬剤: Afatinib / Cisplatin / Pemetrexed
• 関連試験: LUX-Lung-7 (Afatinib vs Gefitinib) / FLAURA (Osimertinib 1L) / NEJ002 / WJTOG3405 / IPASS
• 関連遺伝子: EGFR (ex19del, L858R, G719X, L861Q, S768I)
• ドメイン: lung-cancer-treatment

関連論文

直近 30 件のみ表示中 (関連 37 件)。 全件は MOC ページ または Obsidian (source Markdown) から辿れます。

Basic-Oncogene and genetics

• Du et al. MolCancer 2018 — Mechanisms of receptor tyrosine kinase activation in cancer

Clinical-Epidemiology

• Powell et al. AmJRespirCritCareMed 2013 — Update in lung cancer and mesothelioma 2012

Clinical-NSCLC-ALK

• Yoshida et al. JClinOncol 2016 — Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer

Clinical-NSCLC-Driver negative

• Soria et al. LancetOncol 2015 — Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung

Clinical-NSCLC-Driver-Other

• Johnson et al. JClinOncol 2014 — Recent clinical advances in lung cancer management

Clinical-NSCLC-EGFR

• Paz-Ares et al. AnnOncol 2017 — Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer overall survival
• Hastings et al. AnnOncol 2019 — EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
• Watanabe et al. AnticancerRes 2018 — Phase I study evaluating the combination of afatinib with carboplatin and pemetrexed after first-line EGFR-TKIs
• Kobayashi et al. CancerSci 2016 — Not all epidermal growth factor receptor mutations in lung cancer are created equal perspectives for individualized
• Rolfo et al. CancerTreatRev 2014 — Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors
• Lim et al. CancerTreatRev 2018 — Acquired resistance to EGFR targeted therapy in non-small cell lung cancer mechanisms and therapeutic strategies
• Lee et al. JClinOncol 2015 — Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after
• Cho et al. JClinOncol 2020 — Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations A multicenter, open-label,
• Haratake et al. JTOClinResRep 2020 — Optimizing sequential treatment with EGFR tyrosine kinase inhibitor with a simulation of the T790M mutation rate in
• Hoffknecht et al. JThoracOncol 2015 — Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase
• Wu et al. LancetOncol 2014 — Afatinib versus cisplatin plus gemcitabine for first-line treatment of asian patients with advanced non-small-cell lung
• Tan et al. LancetOncol 2015 — Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer
• Yang et al. LancetOncol 2015 — Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-lung 3 and LUX-lung 6)
• Yang et al. LancetOncol 2015 — Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations a
• Wu et al. LancetOncol 2017 — Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung
• Fukuhara et al. LungCancer 2015 — Factors associated with a poor response to gefitinib in the NEJ002 study smoking and the L858R mutation
• Akamatsu et al. LungCancer 2019 — Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients
• Schuler et al. LungCancer 2019 — First-line afatinib for advanced EGFRm+ NSCLC analysis of long-term responders in the LUX-lung 3, 6, and 7 trials
• Kobayashi et al. MolCancerTher 2017 — Characterization of EGFR T790M, L792F, and C797S mutations as mechanisms of acquired resistance to afatinib in lung
• Mok et al. NEnglJMed 2017 — Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer
• Soria et al. NEnglJMed 2018 — Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer
• Ahluwalia et al. Oncologist 2018 — Epidermal growth factor receptor tyrosine kinase inhibitors for central nervous system metastases from non-small cell
• Asao et al. RespirInvestig 2019 — Resistance to molecularly targeted therapy in non-small-cell lung cancer
• Carnio et al. SeminOncol 2014 — Extending survival of stage IV non-small cell lung cancer

Clinical-irAE

• Cosmai et al. JNephrol 2015 — Renal toxicity of anticancer agents targeting HER2 and EGFR